Search
Even as a child, physician-scientist Veronica Rotemberg always knew that her future self would be wearing a lab coat. Learn more about her journey and research.
For many patients, time is of the essence. At MSK, patients have access to potentially lifesaving therapies long before they are available at community hospitals. Learn how MSK’s Cancer Health Equity Research Program (CHERP) partners with a network of public hospitals in New York City to recruit underserved patients for clinical trials at MSK and give them access to world-class care.
Select patients with papillary thyroid carcinoma with clinically involved lateral neck nodes may not require prophylactic central compartment neck dissection, enhancing quality of life.
Viviane Tabar, MD, has been named the new Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center (MSK). Dr. Tabar has been a vital faculty member at MSK for more than 15 years and is currently the Theresa C. Feng Chair for Neurosurgical Oncology and the Vice Chair for Neurosurgical Research and Education.
Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.
Memorial Sloan Kettering Cancer Center (MSK) today announced that Shelly Anderson, MPM, will join the institution as the inaugural Hospital President on September 25. Anderson joins MSK from Brigham and Women’s Hospital (BWH) in Boston, where she has been a member of the executive leadership team since 2011, most recently serving as Executive Vice President and Chief Operating Officer.
The event featured scientific talks from leading women in science, including winners of this year’s Kravis WISE fellowships.
The Tri-Institutional Stem Cell Initiative, comprised of three leading New York City biomedical research institutions -- Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Medical College of Cornell University -- has announced the first wave of stem cell research projects to be funded through a $50 million gift from The Starr Foundation.
A collaborative team from MSK has uncovered important new findings that explain why ovarian cancer does not respond to immunotherapy.
The engineered immune cells secrete powerful drugs as a layer of defense.